Elaine Kingwell

List of Publications by Year
in descending order

70 papers	2,980 citations	186265 28 h-index	168389 53 g-index
70 all docs	70 docs citations	70 times ranked	3834 citing authors

#	Article	IF	Citations
1	Incidence and prevalence of multiple sclerosis in Europe: a systematic review. BMC Neurology, 2013, 13, 128.	1.8	392
2	Association Between Use of Interferon Beta and Progression of Disability in Patients With Relapsing-Remitting Multiple Sclerosis. JAMA - Journal of the American Medical Association, 2012, 308, 247-56.	7.4	234
3	The natural history of secondary progressive multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 1039-1043.	1.9	191
4	Incidence and Prevalence of Multiple Sclerosis in the Americas: A Systematic Review. Neuroepidemiology, 2013, 40, 195-210.	2.3	169
5	The natural history of primary progressive multiple sclerosis. Neurology, 2009, 73, 1996-2002.	1.1	156
6	Age Related Multiple Sclerosis Severity Score: Disability ranked by age. Multiple Sclerosis Journal, 2017, 23, 1938-1946.	3.0	107
7	Health-care use before a first demyelinating event suggestive of a multiple sclerosis prodrome: a matched cohort study. Lancet Neurology, The, 2017, 16, 445-451.	10.2	105
8	High incidence and increasing prevalence of multiple sclerosis in British Columbia, Canada: findings from over two decades (1991â€"2010). Journal of Neurology, 2015, 262, 2352-2363.	3.6	100
9	Cancer risk in multiple sclerosis: findings from British Columbia, Canada. Brain, 2012, 135, 2973-2979.	7.6	82
10	Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 1050-1056.	1.9	80
11	Examining the effects of comorbidities on disease-modifying therapy use in multiple sclerosis. Neurology, 2016, 86, 1287-1295.	1.1	79
12	Infection-related health care utilization among people with and without multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 1506-1516.	3.0	76
13	Comparison of Statistical Approaches for Dealing With Immortal Time Bias in Drug Effectiveness Studies. American Journal of Epidemiology, 2016, 184, 325-335.	3.4	68
14	Effects of physical comorbidities on disability progression in multiple sclerosis. Neurology, 2018, 90, e419-e427.	1.1	67
15	Five years before multiple sclerosis onset: Phenotyping the prodrome. Multiple Sclerosis Journal, 2019, 25, 1092-1101.	3.0	66
16	Marginal Structural Cox Models for Estimating the Association Between β-Interferon Exposure and Disease Progression in a Multiple Sclerosis Cohort. American Journal of Epidemiology, 2014, 180, 160-171.	3.4	61
17	Adherence and persistence to drug therapies for multiple sclerosis: A population-based study. Multiple Sclerosis and Related Disorders, 2016, 8, 78-85.	2.0	53
18	Predicting risk of secondary progression in multiple sclerosis: A nomogram. Multiple Sclerosis Journal, 2019, 25, 1102-1112.	3.0	53

#	Article	IF	Citations
19	Temporal trends of disability progression in multiple sclerosis: findings from British Columbia, Canada (1975â€"2009). Multiple Sclerosis Journal, 2012, 18, 442-450.	3.0	50
20	Evaluating the safety of Î²-interferons in MS. Neurology, 2017, 88, 2310-2320.	1.1	45
21	Socioeconomic status and disability progression in multiple sclerosis. Neurology, 2019, 92, e1497-e1506.	1.1	45
22	Language and Behavior in Children with Sotos Syndrome. Journal of the American Academy of Child and Adolescent Psychiatry, 1994, 33, 1307-1315.	0.5	42
23	Multiple Sclerosis in Older Adults: The Clinical Profile and Impact of Interferon Beta Treatment. BioMed Research International, 2015, 2015, 1-11.	1.9	40
24	Factors associated with delay to medical recognition in two Canadian multiple sclerosis cohorts. Journal of the Neurological Sciences, 2010, 292, 57-62.	0.6	37
25	Long-Term Persistence With the Immunomodulatory Drugs for Multiple Sclerosis: A Retrospective Database Study. Clinical Therapeutics, 2012, 34, 341-350.	2.5	36
26	Competing Factors Link to Bone Health in Polycystic Ovary Syndrome: Chronic Low-Grade Inflammation Takes a Toll. Scientific Reports, 2017, 7, 3432.	3.3	34
27	Multiple sclerosis: effect of beta interferon treatment on survival. Brain, 2019, 142, 1324-1333.	7.6	34
28	Fatigue, sleep disorders, anaemia and pain in the multiple sclerosis prodrome. Multiple Sclerosis Journal, 2021, 27, 290-302.	3.0	33
29	Common variation near IRF6 is associated with IFN-Î²-induced liver injury in multiple sclerosis. Nature Genetics, 2018, 50, 1081-1085.	21.4	32
30	Assessment of cancer risk with Î²-interferon treatment for multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 1096-1102.	1.9	29
31	Adherence to disease-modifying therapies for multiple sclerosis and subsequent hospitalizations. Pharmacoepidemiology and Drug Safety, 2017, 26, 702-711.	1.9	27
32	A systematic review of morbidities suggestive of the multiple sclerosis prodrome. Expert Review of Neurotherapeutics, 2020, 20, 799-819.	2.8	26
33	Multiple cause of death analysis in multiple sclerosis. Neurology, 2020, 94, e820-e829.	1.1	25
34	Hospital admissions and MS: temporal trends and patient characteristics. American Journal of Managed Care, 2012, 18, 735-42.	1.1	24
35	Traditional risk factors may not explain increased incidence of myocardial infarction in MS. Neurology, 2019, 92, e1624-e1633.	1.1	23
36	Causes that Contribute to the Excess Mortality Risk in Multiple Sclerosis: A Population-Based Study. Neuroepidemiology, 2020, 54, 131-139.	2.3	22

#	Article	IF	Citations
37	Persistence and adherence to the new oral disease-modifying therapies for multiple sclerosis: A population-based study. Multiple Sclerosis and Related Disorders, 2019, 27, 364-369.	2.0	20
38	Mining healthcare data for markers of the multiple sclerosis prodrome. Multiple Sclerosis and Related Disorders, 2018, 25, 232-240.	2.0	18
39	Age-related decreases in relapses among adults with relapsing-onset multiple sclerosis. Multiple Sclerosis Journal, 2020, 26, 1510-1518.	3.0	18
40	Accurate classification of secondary progression in multiple sclerosis using a decision tree. Multiple Sclerosis Journal, 2021, 27, 1240-1249.	3.0	14
41	Informing Medication Discontinuation Decisions among Older Adults with Relapsing-Onset Multiple Sclerosis. Drugs and Aging, 2020, 37, 225-235.	2.7	12
42	Characteristics of a population-based multiple sclerosis cohort treated with disease-modifying drugs in a universal healthcare setting. Expert Review of Neurotherapeutics, 2021, 21, 131-140.	2.8	11
43	Disease-Modifying Drugs for Multiple Sclerosis and Association With Survival. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	6.0	11
44	Association between beta-interferon exposure and hospital events in multiple sclerosis. Pharmacoepidemiology and Drug Safety, 2014, 23, 1213-1222.	1.9	9
45	Interrogation of the Multiple Sclerosis Prodrome Using High-Dimensional Health Data. Neuroepidemiology, 2020, 54, 140-147.	2.3	9
46	Medication adherence in multiple sclerosis as a potential model for other chronic diseases: a population-based cohort study. BMJ Open, 2021, 11, e043930.	1.9	9
47	Interferons and multiple sclerosis: is it plausible that Î²-IFN treatment could influence the risk of cancer among MS patients?. Expert Review of Neurotherapeutics, 2009, 9, 1263-1265.	2.8	8
48	Characteristics associated with drug-induced liver injury from interferon beta in multiple sclerosis patients. Expert Opinion on Drug Safety, 2014, 13, 1305-1317.	2.4	8
49	Does Molimina Indicate Ovulation? Prospective Data in a Hormonally Documented Single-Cycle in Spontaneously Menstruating Women. International Journal of Environmental Research and Public Health, 2018, 15, 1016.	2.6	8
50	Use of the new oral disease-modifying therapies for multiple sclerosis in British Columbia, Canada: the first five-years. Multiple Sclerosis and Related Disorders, 2018, 25, 57-60.	2.0	8
51	Disparities in management and outcomes of myocardial infarction in multiple sclerosis: A matched cohort study. Multiple Sclerosis Journal, 2020, 26, 1560-1568.	3.0	8
52	Identifying optic neuritis and transverse myelitis using administrative data. Multiple Sclerosis and Related Disorders, 2018, 25, 258-264.	2.0	6
53	Dealing With Treatment-Confounder Feedback and Sparse Follow-up in Longitudinal Studies: Application of a Marginal Structural Model in a Multiple Sclerosis Cohort. American Journal of Epidemiology, 2021, 190, 908-917.	3.4	6
54	Disease-modifying drugs for multiple sclerosis and subsequent health service use. Multiple Sclerosis Journal, 2022, 28, 583-596.	3.0	6

#	Article	IF	Citations
55	Time to wake up and smell the coffee? Coffee consumption and multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 453-453.	1.9	5
56	Higher health care use before a clinically isolated syndrome with or without subsequent MS. Multiple Sclerosis and Related Disorders, 2019, 35, 42-49.	2.0	5
57	Adherence to laboratory monitoring among people taking oral drugs for multiple sclerosis: A Canadian population-based study. Multiple Sclerosis Journal, 2021, 27, 239-249.	3.0	5
58	Interferon Beta and Long-term Disability in Multiple Sclerosis. JAMA Neurology, 2013, 70, 651.	9.0	4
59	Association between the use of selective serotonin reuptake inhibitors and multiple sclerosis disability progression. Pharmacoepidemiology and Drug Safety, 2016, 25, 1150-1159.	1.9	4
60	Effect of adherence to the first-generation injectable immunomodulatory drugs on disability accumulation in multiple sclerosis: a longitudinal cohort study. BMJ Open, 2017, 7, e018612.	1.9	4
61	MRI utilization during the diagnostic and post-diagnostic phases in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2019, 28, 138-144.	2.0	4
62	Care consumption of people with multiple sclerosis: A multichannel sequence analysis in a population-based setting in British Columbia, Canada. Multiple Sclerosis Journal, 2022, 28, 309-322.	3.0	4
63	Disease-Modifying Drug Uptake and Health Service Use in the Ageing MS Population. Frontiers in Immunology, 2021, 12, 794075.	4.8	4
64	A multiple sclerosis disease progression measure based on cumulative disability. Multiple Sclerosis Journal, 2021, 27, 135245852098863.	3.0	3
65	Application of pharmacogenomics to investigate adverse drug reactions to the disease-modifying treatments for multiple sclerosis: a case–control study protocol for dimethyl fumarate-induced lymphopenia. BMJ Open, 2017, 7, e016276.	1.9	2
66	Short-term laboratory and related safety outcomes for the multiple sclerosis oral disease-modifying therapies: an observational study. Expert Opinion on Drug Safety, 2021, 20, 481-487.	2.4	2
67	Perimenopausal Bone Loss: More than Estrogen Depletion. Journal of Bone and Mineral Research, 2001, 16, 2365-2366.	2.8	1
68	Alemtuzumab and prescription medication use in the MS population. Multiple Sclerosis and Related Disorders, 2020, 42, 102086.	2.0	1
69	WED 167…Socioeconomic status and progression of disability in ms. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, A21.1-A21.	1.9	0
70	A population-based study comparing multiple sclerosis clinic users and non-users in British Columbia, Canada. International Journal of Population Data Science, 2017, 1, 28.	0.1	0